Stay updated on MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.

Latest updates to the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page
- ChecktodayChange Detected- Revision updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.0%

- Check7 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.4.2 replaces the older Revision: v3.4.0 on the page, indicating a version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check50 days agoChange DetectedUI updates add a 'Show glossary' option and update QC-related fields (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with the revision updated to v3.4.0 (from v3.3.4).SummaryDifference0.1%

- Check64 days agoChange DetectedA minor revision banner update was made: Revision v3.3.4 was added and Revision v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check85 days agoChange DetectedThe study locations were expanded to include many new sites across the US, Canada, and other regions, and the HHS Vulnerability Disclosure link was removed.SummaryDifference2%

Stay in the know with updates to MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.